Tuberculosis treatment and drug regimens

Tuberculosis is an airborne infectious disease treated with combination therapeutic regimens. Adherence to long-term antituberculosis therapy is crucial for maintaining adequate blood drug level. The emergence and spread of drug-resistant Mycobacterium tuberculosis strains are mainly favored by the...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cold Spring Harbor perspectives in medicine Jg. 5; H. 5; S. a017822
Hauptverfasser:	Sotgiu, Giovanni, Centis, Rosella, D'ambrosio, Lia, Migliori, Giovanni Battista
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States 01.05.2015
Schlagworte:	Antitubercular Agents - administration & dosage Antitubercular Agents - adverse effects China Diarylquinolines - administration & dosage Diarylquinolines - adverse effects Humans India Mycobacterium tuberculosis - drug effects Nitroimidazoles - administration & dosage Nitroimidazoles - adverse effects Oxazoles - administration & dosage Oxazoles - adverse effects Tuberculosis, Multidrug-Resistant - drug therapy USSR China USSR India
ISSN:	2157-1422, 2472-5412
Online-Zugang:	Weitere Angaben
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Abstract	Tuberculosis is an airborne infectious disease treated with combination therapeutic regimens. Adherence to long-term antituberculosis therapy is crucial for maintaining adequate blood drug level. The emergence and spread of drug-resistant Mycobacterium tuberculosis strains are mainly favored by the inadequate medical management of the patients. The therapeutic approach for drug-resistant tuberculosis is cumbersome, because of the poor, expensive, less-effective, and toxic alternatives to the first-line drugs. New antituberculosis drugs (bedaquiline and delamanid) have been recently approved by the health authorities, but they cannot represent the definitive solution to the clinical management of drug-resistant tuberculosis forms, particularly in intermediate economy settings where the prevalence of drug resistance is high (China, India, and former Soviet Union countries). New research and development activities are urgently needed. Public health policies are required to preserve the new and old therapeutic options.
AbstractList	Tuberculosis is an airborne infectious disease treated with combination therapeutic regimens. Adherence to long-term antituberculosis therapy is crucial for maintaining adequate blood drug level. The emergence and spread of drug-resistant Mycobacterium tuberculosis strains are mainly favored by the inadequate medical management of the patients. The therapeutic approach for drug-resistant tuberculosis is cumbersome, because of the poor, expensive, less-effective, and toxic alternatives to the first-line drugs. New antituberculosis drugs (bedaquiline and delamanid) have been recently approved by the health authorities, but they cannot represent the definitive solution to the clinical management of drug-resistant tuberculosis forms, particularly in intermediate economy settings where the prevalence of drug resistance is high (China, India, and former Soviet Union countries). New research and development activities are urgently needed. Public health policies are required to preserve the new and old therapeutic options. Tuberculosis is an airborne infectious disease treated with combination therapeutic regimens. Adherence to long-term antituberculosis therapy is crucial for maintaining adequate blood drug level. The emergence and spread of drug-resistant Mycobacterium tuberculosis strains are mainly favored by the inadequate medical management of the patients. The therapeutic approach for drug-resistant tuberculosis is cumbersome, because of the poor, expensive, less-effective, and toxic alternatives to the first-line drugs. New antituberculosis drugs (bedaquiline and delamanid) have been recently approved by the health authorities, but they cannot represent the definitive solution to the clinical management of drug-resistant tuberculosis forms, particularly in intermediate economy settings where the prevalence of drug resistance is high (China, India, and former Soviet Union countries). New research and development activities are urgently needed. Public health policies are required to preserve the new and old therapeutic options.Tuberculosis is an airborne infectious disease treated with combination therapeutic regimens. Adherence to long-term antituberculosis therapy is crucial for maintaining adequate blood drug level. The emergence and spread of drug-resistant Mycobacterium tuberculosis strains are mainly favored by the inadequate medical management of the patients. The therapeutic approach for drug-resistant tuberculosis is cumbersome, because of the poor, expensive, less-effective, and toxic alternatives to the first-line drugs. New antituberculosis drugs (bedaquiline and delamanid) have been recently approved by the health authorities, but they cannot represent the definitive solution to the clinical management of drug-resistant tuberculosis forms, particularly in intermediate economy settings where the prevalence of drug resistance is high (China, India, and former Soviet Union countries). New research and development activities are urgently needed. Public health policies are required to preserve the new and old therapeutic options.
Author	Centis, Rosella D'ambrosio, Lia Sotgiu, Giovanni Migliori, Giovanni Battista
Author_xml	– sequence: 1 givenname: Giovanni surname: Sotgiu fullname: Sotgiu, Giovanni organization: Clinical Epidemiology and Medical Statistics Unit, Department of Biomedical Sciences, University of Sassari, Research, Medical Education and Professional Development Unit, AOU Sassari 07100, Italy – sequence: 2 givenname: Rosella surname: Centis fullname: Centis, Rosella organization: World Health Organization Collaborating Centre for Tuberculosis and Lung Diseases, Fondazione S. Maugeri, Care and Research Institute, Tradate 21049, Italy – sequence: 3 givenname: Lia surname: D'ambrosio fullname: D'ambrosio, Lia organization: World Health Organization Collaborating Centre for Tuberculosis and Lung Diseases, Fondazione S. Maugeri, Care and Research Institute, Tradate 21049, Italy – sequence: 4 givenname: Giovanni Battista surname: Migliori fullname: Migliori, Giovanni Battista organization: World Health Organization Collaborating Centre for Tuberculosis and Lung Diseases, Fondazione S. Maugeri, Care and Research Institute, Tradate 21049, Italy
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/25573773$$D View this record in MEDLINE/PubMed
BookMark	eNo1j0lLA0EUhBuJmBjzCwSZYy4T-73eZo4S3CDgJZ6HXl7iyGx2zxz89w6odami-Cioa7bo-o4YuwW-A-Bw79PHQDEN5Med5WAKxAu2QmkwVxJwMWdQJgeJuGSblD75LKV1YfgVW6JSRhgjVmx7nBxFPzV9qlM2RrJjS92Y2S5kIU7nLNK5npt0wy5Ptkm0-fM1e396PO5f8sPb8-v-4ZB7ydWYy9KF0qPzXqFT-iSkEAIAHFfK68JiqaEsrPelE4JMKIIjFZBOIJUGS7hm29_dIfZfE6WxauvkqWlsR_2UKtClgEJoLmf07g-dXEuhGmLd2vhd_b_DH2FlVbI
CitedBy_id	crossref_primary_10_1080_08927022_2025_2499615 crossref_primary_10_21292_2075_1230_2021_99_7_41_47 crossref_primary_10_1134_S1068162023603257 crossref_primary_10_3390_app10072339 crossref_primary_10_1007_s10867_025_09685_7 crossref_primary_10_1515_pac_2018_0704 crossref_primary_10_1016_j_jmgm_2020_107768 crossref_primary_10_1016_j_tube_2020_101986 crossref_primary_10_1016_j_bmcl_2019_01_004 crossref_primary_10_7759_cureus_35154 crossref_primary_10_1128_spectrum_02592_22 crossref_primary_10_3390_molecules24050892 crossref_primary_10_1002_slct_202000294 crossref_primary_10_1186_s12879_024_10193_7 crossref_primary_10_3390_nu17111878 crossref_primary_10_3390_polym15132774 crossref_primary_10_3390_vaccines11051013 crossref_primary_10_3389_fmicb_2020_01644 crossref_primary_10_52711_0974_360X_2025_00098 crossref_primary_10_7759_cureus_53796 crossref_primary_10_1038_s41598_023_29648_z crossref_primary_10_1208_s12249_023_02510_1 crossref_primary_10_1016_j_lfs_2022_120734 crossref_primary_10_1093_infdis_jiaa625 crossref_primary_10_1016_j_ocl_2023_09_007 crossref_primary_10_1080_23311916_2020_1742853 crossref_primary_10_3389_fchem_2025_1531152 crossref_primary_10_1016_j_susmat_2024_e01037 crossref_primary_10_1002_cnma_202400296 crossref_primary_10_1111_tid_14242 crossref_primary_10_1080_07373937_2024_2437690 crossref_primary_10_1007_s00396_025_05382_y crossref_primary_10_1007_s10620_020_06653_0 crossref_primary_10_3389_fimmu_2024_1437901 crossref_primary_10_1371_journal_ppat_1009452 crossref_primary_10_1038_s41598_023_35930_x crossref_primary_10_1038_nri_2017_112 crossref_primary_10_3390_M1143 crossref_primary_10_1016_j_mtbio_2025_101616 crossref_primary_10_1007_s12291_022_01044_w crossref_primary_10_1007_s12602_025_10608_0 crossref_primary_10_1016_j_cca_2024_119701 crossref_primary_10_1007_s11030_022_10436_2 crossref_primary_10_4103_ijmy_ijmy_29_25 crossref_primary_10_1128_aac_00126_25 crossref_primary_10_1016_j_heliyon_2023_e13324 crossref_primary_10_1038_s41429_020_0293_6 crossref_primary_10_2174_1874467211666181025141114 crossref_primary_10_1038_s41579_022_00731_y crossref_primary_10_1080_17476348_2020_1794827 crossref_primary_10_3390_antibiotics6010003 crossref_primary_10_1007_s42452_022_05010_2 crossref_primary_10_1016_j_biopha_2018_08_101 crossref_primary_10_1016_j_envpol_2019_113472 crossref_primary_10_1038_s41598_022_16468_w crossref_primary_10_1111_cbdd_13865 crossref_primary_10_2147_IJN_S241183 crossref_primary_10_1039_D2SC06858C crossref_primary_10_7759_cureus_76397 crossref_primary_10_1080_17460441_2025_2531229 crossref_primary_10_4103_ijmy_ijmy_184_19 crossref_primary_10_2174_1570180819666220929122614 crossref_primary_10_3389_fimmu_2020_01790 crossref_primary_10_1080_02648725_2022_2076031 crossref_primary_10_3889_oamjms_2021_5839 crossref_primary_10_3390_molecules25133011 crossref_primary_10_1038_s41598_017_05878_w crossref_primary_10_1016_j_jgar_2020_10_006 crossref_primary_10_3389_fphar_2021_628705 crossref_primary_10_1007_s40262_025_01537_w crossref_primary_10_52711_2231_5659_2023_00057 crossref_primary_10_1016_j_ijtb_2020_07_017 crossref_primary_10_1016_j_micres_2023_127393 crossref_primary_10_1016_j_heliyon_2024_e23981 crossref_primary_10_1016_j_bioadv_2022_213269 crossref_primary_10_1016_j_ebiom_2019_10_014 crossref_primary_10_1186_s12941_017_0239_4 crossref_primary_10_1111_cts_12718 crossref_primary_10_1287_opre_2021_2227 crossref_primary_10_3390_ijms21207683 crossref_primary_10_1128_AAC_01445_20 crossref_primary_10_1016_j_lfs_2025_123546 crossref_primary_10_1002_asia_202400944 crossref_primary_10_1016_j_ijtb_2025_01_001 crossref_primary_10_1016_j_molstruc_2023_135556 crossref_primary_10_3390_cells9122695 crossref_primary_10_1007_s10930_020_09885_1 crossref_primary_10_1186_s12859_019_3045_5 crossref_primary_10_2147_PPA_S277650 crossref_primary_10_1039_C9RA10663D crossref_primary_10_1007_s00216_021_03702_z crossref_primary_10_1002_biof_2151 crossref_primary_10_1007_s00044_021_02733_6 crossref_primary_10_1016_j_bioorg_2021_104786 crossref_primary_10_1128_AAC_03016_15 crossref_primary_10_20473_jkr_v10i1_69932 crossref_primary_10_3390_metabo15060355 crossref_primary_10_1371_journal_pone_0227224 crossref_primary_10_3390_vaccines7030080 crossref_primary_10_1016_j_isci_2025_112537 crossref_primary_10_1080_08927022_2024_2406949 crossref_primary_10_1590_s1678_9946201961021 crossref_primary_10_4239_wjd_v15_i5_853 crossref_primary_10_1016_j_ejmech_2021_114066 crossref_primary_10_1007_s11094_025_03422_z crossref_primary_10_1016_j_ijbiomac_2022_02_121 crossref_primary_10_3390_ph17070943 crossref_primary_10_3889_oamjms_2022_10466 crossref_primary_10_1007_s12010_020_03374_y crossref_primary_10_1080_09273948_2025_2509717 crossref_primary_10_1038_s42003_024_06785_3 crossref_primary_10_1128_spectrum_00781_24 crossref_primary_10_53879_id_62_07_15306 crossref_primary_10_3390_scipharm89020020 crossref_primary_10_3390_molecules25051205 crossref_primary_10_1016_j_jconrel_2022_06_005 crossref_primary_10_1177_20420986211041277 crossref_primary_10_3390_ijms24065202 crossref_primary_10_1016_j_sajb_2024_04_022 crossref_primary_10_1080_07391102_2019_1657499 crossref_primary_10_3389_fimmu_2021_665785 crossref_primary_10_1016_j_ejphar_2021_174436 crossref_primary_10_3390_ph18040513 crossref_primary_10_1007_s00005_022_00648_7 crossref_primary_10_1016_j_cnsns_2023_107162 crossref_primary_10_7759_cureus_64496 crossref_primary_10_1016_j_ocl_2023_11_002
ContentType	Journal Article
Copyright	Copyright © 2015 Cold Spring Harbor Laboratory Press; all rights reserved.
Copyright_xml	– notice: Copyright © 2015 Cold Spring Harbor Laboratory Press; all rights reserved.
DBID	CGR CUY CVF ECM EIF NPM 7X8
DOI	10.1101/cshperspect.a017822
DatabaseName	Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE MEDLINE - Academic
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	no_fulltext_linktorsrc
Discipline	Medicine
EISSN	2472-5412
ExternalDocumentID	25573773
Genre	Journal Article Review
GeographicLocations	China USSR India
GeographicLocations_xml	– name: USSR – name: China – name: India
GroupedDBID	53G 5VS ACLKE ADBBV AENEX ALMA_UNASSIGNED_HOLDINGS BAWUL BTFSW CGR CUY CVF DIK EBS ECM EIF EJD GX1 H13 HYE KQ8 MV1 NPM OK1 RCX RHI RPM 7X8
ID	FETCH-LOGICAL-c405t-49bd9c2bcc52b56f34333111b055c68a296198acc9b33e7d8dbe5d2ef14561ae2
IEDL.DBID	7X8
ISICitedReferencesCount	144
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000355198800003&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	2157-1422
IngestDate	Fri Jul 11 08:18:23 EDT 2025 Mon Jul 21 05:48:06 EDT 2025
IsDoiOpenAccess	false
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	5
Language	English
License	Copyright © 2015 Cold Spring Harbor Laboratory Press; all rights reserved.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c405t-49bd9c2bcc52b56f34333111b055c68a296198acc9b33e7d8dbe5d2ef14561ae2
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23
OpenAccessLink	http://perspectivesinmedicine.cshlp.org/content/5/5/a017822.full.pdf
PMID	25573773
PQID	1693183604
PQPubID	23479
ParticipantIDs	proquest_miscellaneous_1693183604 pubmed_primary_25573773
PublicationCentury	2000
PublicationDate	2015-05-01
PublicationDateYYYYMMDD	2015-05-01
PublicationDate_xml	– month: 05 year: 2015 text: 2015-05-01 day: 01
PublicationDecade	2010
PublicationPlace	United States
PublicationPlace_xml	– name: United States
PublicationTitle	Cold Spring Harbor perspectives in medicine
PublicationTitleAlternate	Cold Spring Harb Perspect Med
PublicationYear	2015
References	4572586 - Bull N Y Acad Med. 1973 Mar;49(3):163-96 23459487 - Antimicrob Agents Chemother. 2013 May;57(5):2199-203 22033020 - Lancet. 2012 Feb 25;379(9817):773-5 10529902 - Int J Tuberc Lung Dis. 1999 Oct;3(10 Suppl 2):S231-79 22670901 - N Engl J Med. 2012 Jun 7;366(23):2151-60 22997218 - Eur Respir J. 2013 Jun;41(6):1386-92 6635432 - Rev Infect Dis. 1983 Jul-Aug;5 Suppl 3:S402-6 17021304 - J R Soc Med. 2006 Oct;99(10):531-4 4135686 - Lancet. 1974 Aug 3;2(7875):237-40 21001772 - N Engl J Med. 1946 Aug 15;235(7):220-9 22403262 - J Antimicrob Chemother. 2012 Jun;67(6):1503-7 21828024 - Eur Respir J. 2011 Sep;38(3):516-28 22430968 - Antimicrob Agents Chemother. 2012 Jun;56(6):3027-31 16056018 - Clin Orthop Relat Res. 2005 Aug;(437):3-6 22279595 - PLoS One. 2012;7(1):e30479 22828484 - Lancet. 2012 Sep 15;380(9846):955-7 22191526 - Ann N Y Acad Sci. 2011 Dec;1241:48-70 22828481 - Lancet. 2012 Sep 15;380(9846):986-93 23018916 - Eur Respir J. 2013 Jun;41(6):1393-400 22127584 - J Antimicrob Chemother. 2012 Mar;67(3):633-7 22762423 - Int J Tuberc Lung Dis. 2012 Aug;16(8):1005-14 5778935 - Br Med J. 1969 Apr 19;2(5650):137-41 21682970 - Int J Tuberc Lung Dis. 2011 Jul;15(7):949-54 23422415 - Curr Opin Pulm Med. 2013 May;19(3):266-72 22825115 - Antimicrob Agents Chemother. 2012 Oct;56(10):5142-8 11913920 - Med J Aust. 2002 Feb 18;176(4):176-8 19282348 - Eur Respir J. 2009 Aug;34(2):387-93 13812930 - Br Med J. 1960 Sep 3;2(5200):679-87 20608757 - Clin Pharmacokinet. 2010 Aug;49(8):559-65 22869168 - Nat Med. 2012 Aug;18(8):1157 6348993 - Thorax. 1983 May;38(5):326-32 24293417 - Eur Respir J. 2013 Dec;42(6):1449-53 23144818 - PLoS One. 2012;7(11):e47370 23776831 - Int J Appl Basic Med Res. 2013 Jan;3(1):1-2 22391540 - Antimicrob Agents Chemother. 2012 Jun;56(6):3271-6 19564358 - Antimicrob Agents Chemother. 2009 Nov;53(11):4789-93 19651787 - J Antimicrob Chemother. 2009 Oct;64(4):879-83; author reply 883-4 22496332 - Eur Respir J. 2012 Dec;40(6):1430-42 16949809 - Respir Med. 2006 Nov;100(11):1862-70 5296380 - Bull World Health Organ. 1966;34(4):533-51 19494215 - N Engl J Med. 2009 Jun 4;360(23):2397-405 13194851 - Q J Med. 1954 Jul;23(91):347-66
References_xml	– reference: 22828481 - Lancet. 2012 Sep 15;380(9846):986-93 – reference: 22828484 - Lancet. 2012 Sep 15;380(9846):955-7 – reference: 22403262 - J Antimicrob Chemother. 2012 Jun;67(6):1503-7 – reference: 6635432 - Rev Infect Dis. 1983 Jul-Aug;5 Suppl 3:S402-6 – reference: 16056018 - Clin Orthop Relat Res. 2005 Aug;(437):3-6 – reference: 21828024 - Eur Respir J. 2011 Sep;38(3):516-28 – reference: 22391540 - Antimicrob Agents Chemother. 2012 Jun;56(6):3271-6 – reference: 22033020 - Lancet. 2012 Feb 25;379(9817):773-5 – reference: 22191526 - Ann N Y Acad Sci. 2011 Dec;1241:48-70 – reference: 22869168 - Nat Med. 2012 Aug;18(8):1157 – reference: 24293417 - Eur Respir J. 2013 Dec;42(6):1449-53 – reference: 23459487 - Antimicrob Agents Chemother. 2013 May;57(5):2199-203 – reference: 22496332 - Eur Respir J. 2012 Dec;40(6):1430-42 – reference: 5296380 - Bull World Health Organ. 1966;34(4):533-51 – reference: 22670901 - N Engl J Med. 2012 Jun 7;366(23):2151-60 – reference: 13812930 - Br Med J. 1960 Sep 3;2(5200):679-87 – reference: 23422415 - Curr Opin Pulm Med. 2013 May;19(3):266-72 – reference: 16949809 - Respir Med. 2006 Nov;100(11):1862-70 – reference: 13194851 - Q J Med. 1954 Jul;23(91):347-66 – reference: 10529902 - Int J Tuberc Lung Dis. 1999 Oct;3(10 Suppl 2):S231-79 – reference: 23018916 - Eur Respir J. 2013 Jun;41(6):1393-400 – reference: 19651787 - J Antimicrob Chemother. 2009 Oct;64(4):879-83; author reply 883-4 – reference: 23144818 - PLoS One. 2012;7(11):e47370 – reference: 22127584 - J Antimicrob Chemother. 2012 Mar;67(3):633-7 – reference: 22825115 - Antimicrob Agents Chemother. 2012 Oct;56(10):5142-8 – reference: 22762423 - Int J Tuberc Lung Dis. 2012 Aug;16(8):1005-14 – reference: 4572586 - Bull N Y Acad Med. 1973 Mar;49(3):163-96 – reference: 4135686 - Lancet. 1974 Aug 3;2(7875):237-40 – reference: 5778935 - Br Med J. 1969 Apr 19;2(5650):137-41 – reference: 22997218 - Eur Respir J. 2013 Jun;41(6):1386-92 – reference: 19282348 - Eur Respir J. 2009 Aug;34(2):387-93 – reference: 21001772 - N Engl J Med. 1946 Aug 15;235(7):220-9 – reference: 22430968 - Antimicrob Agents Chemother. 2012 Jun;56(6):3027-31 – reference: 21682970 - Int J Tuberc Lung Dis. 2011 Jul;15(7):949-54 – reference: 6348993 - Thorax. 1983 May;38(5):326-32 – reference: 22279595 - PLoS One. 2012;7(1):e30479 – reference: 20608757 - Clin Pharmacokinet. 2010 Aug;49(8):559-65 – reference: 23776831 - Int J Appl Basic Med Res. 2013 Jan;3(1):1-2 – reference: 19494215 - N Engl J Med. 2009 Jun 4;360(23):2397-405 – reference: 11913920 - Med J Aust. 2002 Feb 18;176(4):176-8 – reference: 17021304 - J R Soc Med. 2006 Oct;99(10):531-4 – reference: 19564358 - Antimicrob Agents Chemother. 2009 Nov;53(11):4789-93
SSID	ssj0000566870
Score	2.494523
SecondaryResourceType	review_article
Snippet	Tuberculosis is an airborne infectious disease treated with combination therapeutic regimens. Adherence to long-term antituberculosis therapy is crucial for...
SourceID	proquest pubmed
SourceType	Aggregation Database Index Database
StartPage	a017822
SubjectTerms	Antitubercular Agents - administration & dosage Antitubercular Agents - adverse effects China Diarylquinolines - administration & dosage Diarylquinolines - adverse effects Humans India Mycobacterium tuberculosis - drug effects Nitroimidazoles - administration & dosage Nitroimidazoles - adverse effects Oxazoles - administration & dosage Oxazoles - adverse effects Tuberculosis, Multidrug-Resistant - drug therapy USSR
Title	Tuberculosis treatment and drug regimens
URI	https://www.ncbi.nlm.nih.gov/pubmed/25573773 https://www.proquest.com/docview/1693183604
Volume	5
WOSCitedRecordID	wos000355198800003&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings	1
isFullTextHit
isPrint
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8NAEB7Uinjx_agvInjwEttks9nNSUQsXlp6qNBb2KcKktSm8fc7m2zrSRC85BAIJJPZmW-eH8CNtYykipMQXa0KE2HxzLlBXWESQbS0tk91QzbBRiM-nWZjn3CrfFvl0iY2hlqXyuXIe25pSOQmDpL72WfoWKNcddVTaKxDhyCUcVrNpnyVY0HnnvKGLw4dGwtdusMvHkJF7KnqbeYHGu-EY6l3BLq_wczG3Qx2__uie7DjgWbw0GrGPqyZ4gC2hr6Ufgi3k1qauao_yuq9Clb95oEodKDn9WvgKBvwTnUEL4OnyeNz6GkTQoXoaxEmmdSZiqVSNJY0tSQhhKBJk31KVcpFnGHQxIVSmSTEMM21NFTHxkYOTAkTH8NGURbmFAJJMfqINMVPQi-WKhFLxDMp7yub2ixKunC9lEGOaulqDaIwZV3lP1LowkkryHzW7s_IMYphhDFy9oenz2EbIQptWwwvoGPxUJpL2FRfi_dqftX8b7yOxsNvDXy0eQ
linkProvider	ProQuest
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Tuberculosis+treatment+and+drug+regimens&rft.jtitle=Cold+Spring+Harbor+perspectives+in+medicine&rft.au=Sotgiu%2C+Giovanni&rft.au=Centis%2C+Rosella&rft.au=D%27ambrosio%2C+Lia&rft.au=Migliori%2C+Giovanni+Battista&rft.date=2015-05-01&rft.eissn=2472-5412&rft.volume=5&rft.issue=5&rft.spage=a017822&rft_id=info:doi/10.1101%2Fcshperspect.a017822&rft_id=info%3Apmid%2F25573773&rft_id=info%3Apmid%2F25573773&rft.externalDocID=25573773
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2157-1422&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2157-1422&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2157-1422&client=summon